Overview Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops Status: Recruiting Trial end date: 2022-01-05 Target enrollment: Participant gender: Summary Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers. Phase: Phase 1 Details Lead Sponsor: Sylentis, S.A.